The identification of a small molecule compound that reduces HIV-1 nef-mediated viral infectivity enhancement

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Chutiwitoonchai, Nopporn ^a   Hiyoshi, Masateru ^a   Mwimanzi, Philip ^a   Ueno, Takamasa ^a   Adachi, Akio ^b   Ode, Hirotaka ^c   Sato, Hironori ^c   Fackler, Oliver T ^d   Okada, Seiji ^a   Suzu, Shinya ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COMPOUND 2C; HEMATOPOIETIC CELL KINASE; NEF PROTEIN; PROLINE; PROTEIN SH3; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PATHOGENESIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; VIRUS INFECTIVITY; WILD TYPE; CELL STRAIN HEK293; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; HUMAN; METABOLISM; PATHOGENICITY; SRC HOMOLOGY DOMAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID MOTIFS; ANTI-HIV AGENTS; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HIV-1; HUMANS; MODELS, MOLECULAR; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROLINE; PROTO-ONCOGENE PROTEINS C-HCK; SRC HOMOLOGY DOMAINS;

EID: 81055125791     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027696     Document Type: Article

References (55)

1. Fackler OT, Baur AS, (2002) Live and let die: Nef functions beyond HIV replication. Immunity 16: 493-497.
2. Peterlin BM, Trono D, (2003) Hide, shield and strike back: how HIV-infected cells avoid immune eradication. Nat Rev Immunol 3: 97-107.
3. Foster JL, Garcia JV, (2008) HIV-1 Nef: at the crossroads. Retrovirology 5: 84.
4. Malim MH, Emerman M, (2008) HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 3: 388-398.
5. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, et al. (1995) Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270: 988-991.
6. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC, (1995) Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 332: 228-232.
7. Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, et al. (1998) Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 95: 163-175.
8. Garcia JV, Miller AD, (1991) Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 350: 508-511.
9. Schaefer MR, Wonderlich ER, Roeth JF, Leonard JA, Collins KL, (2008) HIV-1 Nef targets MHC-I and CD4 for degradation via a final common β-COP-dependent pathway in T cells. PLoS Pathog 4: e1000131.
10. Schwartz O, Maréchal V, Le Gall S, Lemonnier F, Heard JM, (1996) Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 2: 338-342.
11. Greenberg ME, Iafrate AJ, Skowronski J, (1998) The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes. EMBO J 17: 2777-2789.
12. Williams M, Roeth JF, Kasper MR, Filzen TM, Collins KL, (2005) Human immunodeficiency virus type 1 Nef domains required for disruption of major histocompatibility complex class I trafficking are also necessary for coprecipitation of Nef with HLA-A2. J Virol 79: 632-637.
13. Singh RK, Lau D, Noviello CM, Ghosh P, Guatelli JC, (2009) An MHC-I cytoplasmic domain/HIV-1 Nef fusion protein binds directly to the μ subunit of the AP-1 endosomal coat complex. PLoS One 4: e8364.
14. Saksela K, Cheng G, Baltimore D, (1995) Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for downregulation of CD4. EMBO J 14: 484-491.
15. Moarefi I, LaFevre-Bernt M, Sicheri F, Huse M, Lee CH, et al. (1997) Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 385: 650-653.
16. Lerner EC, Smithgall TE, (2002) SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in vivo. Nat Struct Biol 9: 365-369.
17. Suzu S, Harada H, Matsumoto T, Okada S, (2005) HIV-1 Nef interferes with M-CSF receptor signaling through Hck activation and inhibits M-CSF bioactivities. Blood 105: 3230-3237.
18. Hiyoshi M, Suzu S, Yoshidomi Y, Hassan R, Harada H, et al. (2008) Interaction between Hck and HIV-1 Nef negatively regulates cell surface expression of M-CSF receptor. Blood 111: 243-250.
19. Vérollet C, Zhang YM, Le Cabec V, Mazzolini J, Charrière G, et al. (2010) HIV-1 Nef triggers macrophage fusion in a p61Hck- and protease-dependent manner. J Immunol 184: 7030-7039.
20. Chowers MY, Spina CA, Kwoh TJ, Fitch NJ, Richman DD, et al. (1994) Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol 68: 2906-2914.
21. Chowers MY, Pandori MW, Spina CA, Richman DD, Guatelli JC, (1995) The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Virology 212: 451-457.
22. Aiken C, Trono D, (1995) Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 69: 5048-5056.
23. Goldsmith MA, Warmerdam MT, Atchison RE, Miller MD, Greene WC, (1995) Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef. J Virol 69: 4112-4121.
24. Aiken C, (1997) Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 71: 5871-5877.
25. Chazal N, Singer G, Aiken C, Hammarskjöld ML, Rekosh D, (2001) Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. J Virol 75: 4014-4018.
26. Laguette N, Benichou S, Basmaciogullari S, (2009) Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity. J Virol 83: 1093-1104.
27. Olszewski A, Sato K, Aron ZD, Cohen F, Harris A, et al. (2004) Guanidine alkaloid analogs as inhibitors of HIV-1 Nef interactions with p53, actin, and p56lck. Proc Natl Acad Sci U S A 101: 14079-14084.
28. Emert-Sedlak L, Kodama T, Lerner EC, Dai W, Foster C, et al. (2009) Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds. ACS Chem Biol 4: 939-947.
29. Betzi S, Restouin A, Opi S, Arold ST, Parrot I, et al. (2007) Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein. Proc Natl Acad Sci U S A 104: 19256-19261.
30. Hassan R, Suzu S, Hiyoshi M, Takahashi-Makise N, Ueno T, et al. (2009) Dys-regulated activation of a Src tyroine kinase Hck at the Golgi disturbs N-glycosylation of a cytokine receptor Fms. J Cell Physiol 221: 458-468.
31. Dikeakos JD, Atkins KM, Thomas L, Emert-Sedlak L, Byeon IJ, et al. (2010) Small molecule inhibition of HIV-1-induced MHC-I downregulation identifies a temporally regulated switch in Nef action. Mol Biol Cell 21: 3279-3292.
32. Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB, (1994) The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 179: 101-113.
33. Spina CA, Kwoh TJ, Chowers MY, Guatelli JC, Richman DD, (1994) The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med 179: 115-123.
34. Haller C, Tibroni N, Rudolph JM, Grosse R, Fackler OT, (2011) Nef does not inhibit F-actin remodelling and HIV-1 cell-cell transmission at the T lymphocyte virological synapse. Eur J Cell Biol in press.
35. Jere A, Fujita M, Adachi A, Nomaguchi M, (2010) Role of HIV-1 Nef protein for virus replication in vitro. Microbes Infect 12: 65-70.
36. Madrid R, Janvier K, Hitchin D, Day J, Coleman S, et al. (2005) Nef-induced alteration of the early/recycling endosomal compartment correlates with enhancement of HIV-1 infectivity. J Biol Chem 280: 5032-5044.
37. Tokunaga K, Kiyokawa E, Nakaya M, Otsuka N, Kojima A, et al. (1998) Inhibition of human immunodeficiency virus type 1 virion entry by dominant-negative Hck. J Virol 72: 6257-6259.
38. Choi HJ, Smithgall TE, (2004) Conserved residues in the HIV-1 Nef hydrophobic pocket are essential for recruitment and activation of the Hck tyrosine kinase. J Mol Biol 343: 1255-68.
39. Rauch S, Pulkkinen K, Saksela K, Fackler OT, (2008) Human immunodeficiency virus type 1 Nef recruits the guanine exchange factor Vav1 via an unexpected interface into plasma membrane microdomains for association with p21-activated kinase 2 activity. J Virol 82: 2918-2929.
40. Schindler M, Rajan D, Specht A, Ritter C, Pulkkinen K, Saksela K, et al. (2007) Association of Nef with p21-activated kinase 2 is dispensable for efficient human immunodeficiency virus type 1 replication and cytopathicity in ex vivo-infected human lymphoid tissue. J Virol 81: 13005-13014.
41. Pizzato M, Helander A, Popova E, Calistri A, Zamborlini A, et al. (2007) Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. Proc Natl Acad Sci U S A 104: 6812-6817.
42. Bouchet J, Basmaciogullari SE, Chrobak P, Stolp B, Bouchard N, et al. (2011) Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody. Blood 117: 3559-3568.
43. Oneyama C, Agatsuma T, Kanda Y, Nakano H, Sharma SV, et al. (2003) Synthetic inhibitors of proline-rich ligand-mediated protein-protein interaction: potent analogs of UCS15A. Chem Biol 10: 443-451.
44. Akari H, Uchiyama T, Fukumori T, Iida S, Koyama AH, et al. (1999) Pseudotyping human immunodeficiency virus type 1 by vesicular stomatitis virus G protein does not reduce the cell-dependent requirement of vif for optimal infectivity: functional difference between Vif and Nef. J Gen Virol 80: 2945-2959.
45. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, et al. (1987) Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236: 819-822.
46. Chihara T, Suzu S, Hassan R, Chutiwitoonchai N, Hiyoshi M, et al. (2010) IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ 17: 1917-1927.
47. Marti-Renom MA, Stuart AC, Fiser A, Sánchez R, Melo F, et al. (2000) Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 29: 291-325.
48. Baker D, Sali A, (2001) Protein structure prediction and structural genomics. Science 294: 93-96.
49. Shirakawa K, Takaori-Kondo A, Yokoyama M, Izumi T, Matsui M, et al. (2008) Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif. Nat Struct Mol Biol 15: 1184-1191.
50. Grzesiek S, Bax A, Hu JS, Kaufman J, Palmer I, et al. (1997) Refined solution structure and backbone dynamics of HIV-1 Nef. Protein Sci 6: 1248-63.
51. Wang J, Cieplak P, Kollman PA, (2000) How well does a restrained electrostatic potential (RESP) model perform in calcluating conformational energies of organic and biological molecules? J Comput Chem 21: 1049-1074.
52. Labute P, (2008) The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem 29: 1693-1698.
53. Goto J, Kataoka R, Muta H, Hirayama N, (2008) ASEDock-docking based on alpha spheres and excluded volumes. J Chem Inf Model 48: 583-90.
54. Halgren TA, (1999) MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. J Comput Chem 20: 720-29.
55. Halgren TA, (1999) MMFF VI. MMFF94s option for energy minimization studies. J Comput Chem 20: 730-48.